Barry M. Bernstein,Rajeev M. Menon,Amit Khatri,Sven Mensing,Sandeep Dutta,Daniel E. Cohen,Thomas J. Podsadecki,Scott C. Brun,Walid M. Awni,Emily O. Dumas,Cheri E. Klein
申请号：
US13603022
公开号：
US20130102525A1
申请日:
2012.09.04
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
